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Abstract: Fabry disease (FD) is an X-linked lysosomal storage disorder that affects both men 
and women. The manifestations of this heterogeneous disease are multisystemic and progres-
sive. Prior to the development of enzyme replacement therapy, the management and treatment 
for Fabry disease was largely nonspecific and supportive. Because enzyme replacement therapy 
became commercially available in 2001, a variety of clinical benefits in Fabry patients have been 
consistently reported, including improved renal pathology and cardiac function, and reduced 
severity of neuropathic pain and improved pain-related quality of life. This update focuses on 
published data on the efficacy and tolerability of enzyme replacement therapy with agalsidase 
alfa, and gives a brief overview on some of the outstanding management issues in the treatment 
of this complex disease.
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Introduction
Anderson–Fabry disease (FD; OMIM 301500) is a metabolic storage disorder result-
ing from deficient activity of the lysosomal hydrolase, α-galactosidase A (α-gal A).1 
In individuals with defective α-gal A, the lipid substrate globotriaosylceramide (Gb3) 
accumulates in lysosomes throughout the body, resulting in progressive multiple-organ 
pathology.1 Early signs and symptoms characteristic of the enzymatic defect include 
recurrent episodes of acroparesthesia and neuropathic pain crises, angiokeratomas, 
hearing loss and tinnitus, hypohidrosis, and corneal lesions.2 With accumulating Gb3 
deposits in lysosomes and increasing age, premature mortality usually occurs due 
to renal, cardiac, and/or cerebral complications.3 Fabry disease is a rare X-linked 
genetic trait affecting primarily males in all ethnic groups. Affected hemizygous males 
who have no or minimal α-gal A activity exhibit the classic phenotype, with clinical 
manifestations presenting in childhood or adolescence.4 Most heterozygous females 
are affected, although α-gal A activity level and the onset and rate of disease progres-
sion is more variable than for hemizygous males.5,6 In both heterozygous females and 
hemizygous males, lifespan is typically reduced by approximately 15–20 years.3,5 
Classical Fabry disease, first described independently in 1898 by Fabry in Germany7 
and by Anderson in England,8 is a rare disorder, with an estimated incidence of 1 per 
117,000 live births.4,9 The clinical spectrum of classic Fabry disease has expanded in the 
past 15 years due to the discovery of milder phenotypes with residual α-gal A activity, 
resulting in later-onset cardiac and renal manifestations.4,10–13 A recent Italian newborn 
screening study for Fabry disease determined the α-gal A activity in dried blood spots 
of 37,104 consecutive newborn males.4 In this population, Spada et al reported the Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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incidence of α-gal A deficiency to be 15–20 times higher than 
previous estimates.4 Moreover, the higher incidence found by 
newborn screening of later-onset phenotypes compared with 
classic phenotypes (11:1 ratio of later-onset versus classic 
phenotypes, respectively) suggests Fabry disease is currently 
underrecognized.4 Similarly, a newborn screening study by 
Hwu et al screened 90,288 male Taiwanese newborns and 
reported a high incidence of approximately one in 1250 with 
Fabry disease mutations, 86% of which were mutations found 
in later-onset cardiac phenotype patients.14
Due to its rarity, the broad number and severity of 
symptoms, and the heterogeneous phenotypic expressions, 
diagnosis is often challenging, particularly for heterozygous 
females and later-onset phenotypes.4 Future newborn screening 
for Fabry disease, as well as screening of high-risk populations, 
such as male kidney recipients, could be implemented into 
existing screening programs to aid early diagnosis.15
Overall, clinical studies in adult Fabry patients suggest 
that early initiation of enzyme replacement therapy may be 
able to alleviate symptoms and slow disease progression. 
Enzyme replacement therapy appears to normalize Gb3 levels 
in various organs, with numerous reported symptomatic 
benefits.16–19 The Mainz Severity Score Index, which provides 
an overall measure of disease severity, shows a marked 
reduction of Fabry disease severity following at least 1 year 
of enzyme replacement therapy (P , 0.001).17 Fabry disease 
is a progressive disorder, so enzyme replacement therapy 
intervention in childhood has the potential to provide greater 
long-term benefits, such as reducing or eliminating major 
organ damage in later life.2,20,21 More recent studies evaluating 
long-term (up to 4 years of follow-up) enzyme replacement 
therapy in children with Fabry disease demonstrate that 
agalsidase alfa is well tolerated, with efficacy profiles con-
sistent with those reported in adults.2,20,22 However, long-term 
follow-up studies are required to confirm that initiation of 
enzyme replacement therapy for Fabry disease during child-
hood can prevent the irreversible, life-threatening organ 
damage that can occur during adulthood.
Availability of enzyme replacement 
therapy
Two distinct recombinant protein replacement drugs are 
approved for use in Europe for the treatment of Fabry 
patients, ie, agalsidase alfa (Replagal®; Shire Human Genetic 
Therapies, Dublin, Ireland) and agalsidase beta   (Fabrazyme®; 
Genzyme Corporation, Cambridge, MA). Studies have shown 
that the two recombinant enzymes exhibit identical biochemi-
cal properties and are comparable with respect to amino acid 
composition, specific   activity, stability, and uptake by cul-
tured fibroblasts, with only minor differences in glycosylation 
composition and   mannose-6-phosphate receptor-mediated 
cellular uptake.23–25 Both agalsidase alfa and agalsidase beta 
contain recombinant human α-gal A, but they are produced 
differently and are approved for administration at different 
doses (administered as an intravenous infusion every other 
week at 0.2 mg/kg for agalsidase alfa over 40 minutes26 or 
1.0 mg/kg for agalsidase beta over 1.5–4.5 hours).18,27 As 
with other recombinant therapies, human α-gal A treatment 
is expensive, and at the registered dose, the annual cost of 
both drugs is equal at approximately €210,000 per 70 kg 
patient.28 Agalsidase alfa is produced using cultured human 
skin fibroblasts with an activated promoter of the α-gal A 
gene, and agalsidase beta is produced by classical transduc-
tion of Chinese hamster ovary cells with human α-gal A 
cDNA.29,30
In June 2009, Genzyme reported viral contamination in 
the manufacturing process of Fabrazyme, which has led to 
a continuous global shortage of agalsidase beta.31 Updated 
treatment recommendations advising reduced dosing 
regimens have consequently been published by the European 
Medicines Agency for adult male patients currently receiving 
Fabrazyme.31,32 Switching to agalsidase alfa (Replagal) has 
also been initiated for some Fabry patients, with careful 
monitoring. Agalsidase alfa is licensed in Europe, as well 
as in Canada, Japan, New Zealand, and several countries in 
South America.33 It is currently an investigational product in 
the US. The impact of a Fabrazyme shortage and switching 
to Replagal with respect to the clinical outcome is currently 
unknown, and hence will not be discussed further. However, 
clinicians treating patients with Fabry disease continue to be 
in discussion with the European Medicines Agency to ensure 
all individual patients receive the best possible treatment 
option based on their clinical need.
Pharmacology of agalsidase alfa
Few studies have evaluated the pharmacokinetics and 
pharmacodynamics of agalsidase alfa.29 A single intrave-
nous dose of agalsidase alfa 0.2 mg/kg has been shown to 
exhibit a biphasic serum distribution and elimination pro-
file from the circulation in both adults and children.21,29,34 
The pharmacokinetic properties of agalsidase alfa are essen-
tially unaffected by the dose of the enzyme, and were not 
significantly different between male and female patients.29 
Elimination half-lives were 108 ± 17 minutes in males 
compared with 89 ± 28   minutes in females, and volume of 
distribution was approximately 17% body weight in both Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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genders.29 Clearance normalized for body weight was 2.66 
and 2.10 mL/min/kg for males and females, respectively.29 
A short plasma half-life, ,1% of the maximal plasma 
concentration of agalsidase alfa, detectable 8 hours after dos-
ing, has also been reported.29,35,36 The intracellular half-life 
of agalsidase alfa is reported to be 24–48 hours.19
Following six months of agalsidase alfa treatment, 12 of 
28 male patients showed altered pharmacokinetics, including 
an apparent increase in clearance. These changes were 
associated with the development of low titer antibodies to 
agalsidase alfa, but no clinically significant effects on safety 
or efficacy were observed in the patients studied.29 In children 
aged 7–18 years, agalsidase alfa 0.2 mg/kg is cleared faster 
from the circulation than in adult patients with Fabry disease 
(P , 0.0001).21,29
Clinical efficacy in Fabry disease
The evidence of clinical efficacy of agalsidase alfa in Fabry 
disease has been reported in 5 randomized clinical trials, 
13 open-label studies, and 11 reports from the Fabry Out-
come Survey. The Fabry Outcome Survey is one of the most 
comprehensive global observational database on patients 
with Fabry disease. Initiated and sponsored by Shire Human 
Genetic Therapies in 2001, the Fabry Outcome Survey aims 
to increase our understanding of the nature of Fabry disease 
and to improve the clinical management of all Fabry patients, 
including women and children, receiving enzyme replace-
ment therapy with agalsidase alfa. As of September 2010, the 
Fabry Outcome Survey contains data on 1933 patients from 
22 countries (Shire Human Genetic Therapies, data on file), 
and the inclusion criteria have been previously described.37
Table 1 summarizes these studies according to their 
primary endpoints. Plasma and urinary Gb3 levels, renal 
endpoints (including glomerular filtration rate), and cardiac 
and neurological endpoints were most commonly studied. 
The most recent and relevant studies are discussed relating 
to clinical outcome in this section.
Effects on renal function
Renal dysfunction is a major complication of Fabry disease, 
and end-stage renal disease is most common in affected males 
before the fourth decade.3,38,39 A smaller number of heterozy-
gous females also have a poor renal prognosis.5 Gb3 gradually 
accumulates in lysosomes in renal cells, leading to microvas-
cular dysfunction, occlusion, and ischemia, with subsequent 
development of tubular atrophy, segmental and global 
sclerosis, and interstitial fibrosis.38–41 Overall, long-term 
enzyme replacement therapy with agalsidase alfa shows 
stabilization of kidney function in patients with early stages 
of chronic kidney disease at baseline and slowing of pro-
gression of renal function compared with historical control 
subjects, even in male and female patients with advanced 
chronic kidney disease.26,42–44
Agalsidase alfa 0.2 mg/kg every other week was initially 
evaluated in a randomized, double-blind, placebo-controlled 
clinical trial of 26 adult males with Fabry disease.26 Inulin 
clearance and creatinine clearance were used to measure 
glomerular filtration rate at baseline and at week 24.26 
  Following an initial six months of treatment with agalsi-
dase alfa, creatinine clearance increased slightly compared 
with placebo, from 92.7 ± 6.2 mL/min/1.73 m2 at baseline 
to 94.8 ± 7.7 mL/min/1.73 m2 (P = 0.02).26 Similar results 
were observed for glomerular filtration rate estimated by 
inulin clearance, although the results were not statistically 
significant.26 During a long-term, open-label extension of 
this study, glomerular filtration rate was estimated using the 
four-variable Modification of Diet in Renal Disease method 
using serial measurements of serum creatinine.42,45 The mean 
(± standard deviation) estimated glomerular filtration rate of 
patients with Stage I disease (mean baseline estimated glom-
erular filtration rate 108.7 ± 14.1 mL/min/1.73 m2, n = 12) 
or Stage II disease (mean baseline estimated glomerular 
filtration rate 78.6 ± 8.2 mL/min/1.73 m2, n = 8) remained 
relatively stable after 4 years of treatment (mean estimated 
glomerular filtration rate 101.5 ± 12.4 mL/min/1.73 m2 and 
67.1 ± 17.0 mL/min/1.73 m2, for patients with baseline 
Stage I and II disease, respectively).42 During this study, 
a subgroup of patients (n = 4) with more severe kidney 
dysfunction (mean baseline estimated glomerular filtra-
tion rate 47.1 ± 9.4 mL/min/1.73 m2) showed a decrease to 
25.1 ± 16.4 mL/min/1.73 m2, P = 0.098) following 48 months 
of enzyme replacement therapy; representing an average 
rate of decline of approximately 5.2 mL/min/1.73 m2. 
None of the patients with Stage III disease at baseline pro-
gressed to end-stage renal failure during this study. More 
recently, Schiffmann et al demonstrated that after switching 
to a weekly infusion of agalsidase alfa 0.2 mg/kg despite 
2–4 years of conventional treatment of agalsidase alfa 
0.2 mg/kg every 2 weeks, 9 of 11 patients (82%) showed 
either an improvement in estimated glomerular filtration 
rate (n = 3) or a slowing in the rate of estimated glomerular 
filtration rate decline (n = 6); estimated glomerular filtration 
rate was calculated using the four-variable Modification 
of Diet in Renal Disease formula.46 During the 24-month 
follow-up period on weekly dosing, the mean rate of change 
in estimated glomerular filtration rate was observed to slow Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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to -3.3 ± 4.7 mL/min/year (P = 0.01 versus every other 
week). Notably only two patients failed to improve their 
estimated glomerular   filtration rate.46
In a pooled analysis of three randomized, placebo-
  controlled trials and their open-label extension studies involv-
ing male patients, the annual rate of decline in   estimated 
glomerular filtration rate was 7.0 mL/min/1.73 m2 for 
6 months of placebo treatment and 2.9 mL/min/1.73 m2 for 
12–54 months of agalsidase alfa treatment, suggesting that 
agalsidase alfa treatment may slow the natural rate of glom-
erular filtration rate decline in male Fabry patients.47
Several studies from the analysis of patients in the 
Fabry Outcome Survey have reported that treatment with 
agalsidase alfa stabilizes estimated glomerular filtra-
tion rate in both male and female Fabry patients.43,44,48–50 
  Following 3 years of treatment, the overall change in 
estimated glomerular filtration rate for a large number of 
patients (n = 165, including 115 males and 50 females) 
receiving agalsidase alfa was -1.68 mL/min/1.73 m2/year 
for patients with baseline proteinuria ,0.50 g/24 hours 
(n = 40) and -3.98 mL/min/1.73 m2/year for patients with 
baseline   proteinuria .0.50 g/24 hours (n = 14).43 The most 
recent report from the Fabry Outcome Survey describes the 
observations in patients who have been treated with agalsi-
dase alfa for 5 years. The mean annual decline in estimated 
glomerular filtration rate was 2.46 mL/min/1.73 m2 (n = 150, 
males and females).
The efficacy of agalsidase beta replacement   therapy on 
measures of kidney function was evaluated in two randomized 
controlled trials and in open-label studies.51–54 Creatinine 
  clearance and estimated glomerular filtration rate 
remained stable after more than 3 years of treatment with 
agalsidase beta.51,54 Consistent with the results for agalsi-
dase alfa, renal disease progression was observed for some 
patients receiving agalsidase beta who had more advanced 
disease at baseline.51,54
These results suggest that disease progression is related to 
disease severity in Fabry patients, thus early treatment could 
potentially provide greater benefit because there seems to be 
a point of no return, when the enzyme replacement therapy 
response is significantly reduced and renal failure is most 
probably irreversible.16
Effects on cardiac manifestations
Before the development of enzyme replacement therapy, 
cardiac involvement was the most common cause of 
  premature mortality in Fabry disease.55,56 Cardiac hypertrophy, 
arrhythmia, valvular insufficiency, and cardiac conduction Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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abnormalities are common cardiac manifestations in Fabry 
disease.12,55,57 A small number of studies and observational 
data have provided evidence showing that 0.6–4.0 years 
of treatment with agalsidase alfa results in a progressive 
decrease in interventricular septal thickness and a reduction 
or stabilization of left ventricular mass index.48,58–60
The effects of agalsidase alfa on cardiac structure and 
function were assessed in a randomized, double-blind, 
placebo-controlled study. In this study by Hughes et al, 
myocardial Gb3 content and reduction in left ventricular 
mass, as measured by magnetic resonance imaging, was 
assessed in 15 adult male Fabry patients following 6 months 
of enzyme replacement therapy with agalsidase alfa. Ten of 
the 15 patients enrolled had left ventricular hypertrophy 
at baseline, as measured by magnetic resonance imaging. 
Left ventricular mass increased in the placebo group by 21.8 g 
and decreased in the enzyme replacement therapy group by 
11.5 g (P = 0.041). This equated to a mean increase in left 
ventricular mass index for the placebo group of 12 g/m2 com-
pared with a decrease in the treated group of 6.4 g/m2 (P = 0.02 
versus placebo).58 Consistently, there was also a reduction in 
myocardial Gb3 content, albeit not statistically significant.58 
These results were confirmed in the   corresponding 2-year 
open-label extension study. In addition, left ventricular pos-
terior and septal wall thickness was significantly decreased, 
suggesting remodeling had occurred. Throughout the 2-year 
extension trial, significant reductions in plasma Gb3 were 
maintained, reflecting increased metabolism of Gb3 deposits 
and a possible reduction in its pathogenic tissue storage.58 
  Echocardiographic data evaluation revealed a reduction 
in mean ventricular wall thickness (P , 0.05) and height-
  adjusted left ventricular mass (LVM/h) following 1–2 years 
for agalsidase alfa treatment in a large cohort of Fabry 
  Outcome Survey patients with enlarged hearts at baseline.48 
In a case study of four patients (three female heterozygotes 
and one male hemizygote), 18 months of agalsidase alfa 
treatment resulted in a significant continuous reduction in 
left ventricular mass indexed to body surface area (F = 13.67; 
P = 0.002) and mean ventricular wall thickness (F = 8.81; 
P , 0.01).59 More recently, Kampmann et al assessed the 
effectiveness of agalsidase alfa on LVM/h in male and female 
Fabry patients with and without baseline left ventricular 
hypertrophy.61 After 12 months of treatment in Fabry patients 
with left ventricular hypertrophy at baseline (n = 14), LVM/h 
decreased significantly by 9.2 ± 7.9 g/m2.7 (n = 9; P = 0.008). 
After 3 years of treatment in this subgroup, LVM/h decreased 
significantly by 5.1 ± 7.5 g/m2.7 (n = 10; P = 0.037), suggesting 
that enzyme replacement therapy was associated with a 
significant reduction in LVM/h in patients with baseline left 
ventricular hypertrophy.61 After 12 months of treatment, in 
Fabry patients without baseline left ventricular hypertrophy 
(n = 31), LVM/h increased significantly by 3.6 ± 5.7 g/m2.7 
(n = 28; P = 0.002). After 3 years of treatment in this subgroup, 
the increase in LVM/h was not significantly different from 
baseline in 10 patients (2.1 ± 7.9 g/m2.7) suggesting stabiliza-
tion of LVM/h in patients without baseline left ventricular 
hypertrophy. Long-term (up to 5 years) treatment with agal-
sidase alfa in Fabry patients has been reported from the Fabry 
Outcome Survey observational database.44 In this population 
of males and females, stabilization or improvement in left 
ventricular mass index was seen in 71.9% (23/32) patients 
with baseline left ventricular hypertrophy, and in 92% (23/25) 
patients without baseline left ventricular hypertrophy.44 In the 
group of 25 patients without baseline left ventricular hyper-
trophy, agalsidase alfa treatment resulted in small, statistically 
insignificant decreases in mean left ventricular mass index at 
years 1, 2 and 3, and a small, statistically insignificant increase 
in mean left ventricular mass index after 5 years.44 Notably, 
a significant improvement in ventricular function (midwall 
fractional shortening) was observed after years 1, 2, and 3 for 
patients with baseline left ventricular hypertrophy, and after 
1 and 2 years in patients with normal baseline left ventricular 
mass index. Overall, midwall fractional shortening stabilized 
or improved in 62.1% (18/32) of subjects with baseline left 
ventricular hypertrophy, and in 95.2% (20/25) of subjects 
without baseline left ventricular hypertrophy.44
Interestingly, a recent study by Kampmann et al evalu-
ated whether signs of cardiac manifestations were present 
in a population of 20 pediatric patients with Fabry disease 
(aged #18 years).62 Mean baseline LVM/h was 45 ± 2.3 g/m2.7 
and 47 ± 3.4 g/m2.7 in boys (n = 8) and girls (n = 12), respectively. 
All patients had LVM/h2.7 greater than the 75th percentile com-
pared to healthy controls.62 Following a mean follow-up of 26 
months, 85.7% (12/14) patients showed a mean increase of 
7.5 ± 3.2 g/m2.7 in LVM/h. Analyses of heart rate variability 
revealed that male but not female Fabry patients had signifi-
cantly reduced heart rate variability, suggesting a reduction 
in parasympathetic stimulation of the heart (P , 0.05).62 
The authors of this study concluded that progressive cardiac 
involvement is common in pediatric Fabry patients.62
Effects on pain and quality of life
Acute neuropathic pain is a common early symptom of 
Fabry disease and occurs in about 80% of patients.37,63 
Other   neurological manifestations may include abnormal gut 
motility and pain, which have a negative impact on quality Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of life.63,64 Small fiber neuropathy is a cause of neuropathic 
pain.5,65 Acroparesthesia and hypohidrosis can also adversely 
affect quality of life.65,66
The effect of agalsidase alfa 0.2 mg/kg every other week 
on neuropathic pain was initially evaluated in a randomized, 
double-blind, placebo-controlled clinical trial of 26 adult 
males with Fabry disease.26 Following an initial six months 
of treatment with agalsidase alfa, mean (± standard error) 
Brief Pain Inventory severity scores, reported as a primary 
endpoint, declined from 6.2 ± 0.46 to 4.3 ± 0.73, compared 
with no significant change in the placebo group (P = 0.02).26 
Pain-related quality of life was also reduced for patients 
treated with agalsidase alfa versus placebo (P = 0.05).26 
Four of 11 patients treated with agalsidase alfa who were 
taking neuropathic pain medications at baseline discontinued 
these medications after 1–8 weeks compared with none of 
the patients (n = 11) taking neuropathic pain medications and 
receiving placebo (P = 0.03).26 Patients in the placebo group 
experienced a similar decline in Brief Pain Inventory severity 
scores 6 months after receiving agalsidase alfa treatment in 
the open-label extension study.65 No further reductions in 
pain scores were thereafter reported.
Several reports from the Fabry Outcome Survey indicate 
that agalsidase alfa has a beneficial effect on pain and quality 
of life.44,48,63,64 Recent reports from the Fabry Outcome Survey 
show that after 5 years of agalsidase alfa treatment, mean 
average pain was reduced from baseline.44 Reductions were 
significant at 2, 3, and 5 years (P = 0.0015, P = 0.0128, 
and P = 0.023, respectively). Brief Pain Inventory sever-
ity scores also decreased, with significant reductions at 2 
and 5 years (P = 0.0076 and P = 0.0137, respectively).44 
Clinically significant reductions (defined as improvement 
of .1 point on the Brief Pain Inventory) were observed for 
“average pain” (n = 32; 60.4% patients) and “worst pain” 
(n = 26; 53.1% patients).44 The EuroQoL questionnaire 
used to assess quality of life in the Fabry Outcome Survey 
revealed significant improvements compared with baseline 
following 1, 2, and 5 years of enzyme replacement therapy 
(P = 0.0247, P = 0.0026, P = 0.0483, respectively), suggesting 
that agalsidase alfa may improve quality of life in both male 
and female Fabry patients.44
Agalsidase alfa has been reported to provide relief of 
gastrointestinal symptoms, such as abdominal pain and 
diarrhea.67,68 Dehout et al reported a decrease in frequency 
and severity of abdominal pain and diarrhea following 
6 months of agalsidase alfa treatment.67 Following 1 year of 
agalsidase alfa treatment in both Fabry adults and children, 
the prevalence of abdominal pain, present in more than 50% 
of patients (n = 178) prior to enzyme replacement therapy, 
was significantly reduced in adults and children.68
Effects on other organs/systems
ear, nose and throat
Progressive hearing impairment is a common manifestation 
in Fabry disease.69,70 Agalsidase alfa treatment for 6 months 
compared with placebo was reported to reverse hearing 
deterioration for 15 male Fabry patients in a randomized, 
double-blind study.70 In an open-label extension of this study, 
hearing loss slightly improved above baseline by 5 dB after 
30 months of agalsidase alfa treatment (P = 0.004).69
Similarly, Fabry Outcome Survey data (n = 26) show 
improvements of similar magnitude (1 and 7 dB) following 
agalsidase alfa treatment over 12 months in Fabry patients 
with moderately abnormal hearing thresholds at baseline.71 
Hajioff et al conclude that agalsidase alfa treatment can 
stabilize and possibly improve hearing for Fabry patients who 
have not progressed to severe hearing loss.71 Clinical evidence 
is lacking to support any definitive conclusions that enzyme 
replacement therapy has any effect on hearing loss.
Central nervous system
Central nervous system manifestations of Fabry disease 
consist of cerebrovascular disease, including large vessel 
ectasia, large-vessel occlusive disease, and small vessel 
occlusive disease.72
A 3-year, open-label extension study reported that 
agalsidase alfa significantly improved thermal sensation, 
especially in the foot, as well as improved sweat function.65 
A significant improvement in sympathetic skin responses 
in seven male patients during 2 years of agalsidase alfa has 
also been reported.73 Nerve fiber regeneration has not yet 
been observed.74
Data from the Fabry Outcome Survey have demonstrated 
that cerebrovascular disease often coexists with advanced renal 
or cardiac disease.75 A recent prospective study of cryptogenic 
stroke in young adults (n = 721), using an α-gal A enzyme-
screening assay, suggested that up to 1.2% of patients with 
stroke aged between 18–55 years might have Fabry disease.76 
However, the prevalence of unrecognized Fabry disease 
among young patients with ischemic strokes is unknown.76–78 
The significant prevalence rate discrepancies reported in 
these studies (first ischemic stroke, prevalence range 0–2.17) 
is most probably due to differences in study populations, as 
outlined in the Wozniak et al study.77 Atypical variants of 
Fabry disease with late-onset cerebrovascular disease have 
been observed in a Belgian cohort of young patients with Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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cerebrovascular disease, but the clinical relevance of this 
remains unclear at present.79 Cerebrovascular complications 
of stroke and transient ischemic attacks have been reported in 
5%–27% of heterozygous Fabry females.5,37,80 One study has 
shown a higher prevalence of ischemic stroke and transient 
ischemic attacks in female Fabry patients compared with men 
(27% versus 12% for females and males, respectively).37
Changes in cerebral blood flow velocities have been 
published for Fabry patients treated with agalsidase alfa.72,81,82 
Moore et al reported a significant decrease in cerebral 
hypoperfusion versus placebo following 6 months of treat-
ment with agalsidase alfa in a randomized controlled trial 
of 26 male Fabry patients.72,82 No impact on the incidence of 
stroke was reported.72,82 In the open-label extension study, 
Moore et al demonstrated a reduction in elevated cerebral 
blood flow velocities after 18 months of agalsidase alfa 
therapy.81 The relationship between increased risk of stroke 
in Fabry disease and elevated regional cerebral blood flow 
remains unclear.72
Effects in women
In contrast with the long-held assumption that women with 
Fabry disease are rarely symptomatic, the majority of females 
who are heterozygous for disease causing mutations in the 
α-gal A gene report clinical features of Fabry disease.5,6,83 
In one study, severe manifestations of disease were 
reported. For example, 77% of women reported neurological 
involvement, 59% cardiac involvement, and 40% renal 
involvement.83 Results from the Fabry Outcome Survey 
database and the baseline demographic data within it have 
been published recently, demonstrating that enzyme replace-
ment therapy should not be restricted to hemizygous men, 
but should also be considered for heterozygous females and 
children.37 In 165 patients with Fabry neuropathy (including 
50 female patients), Feriozzi et al demonstrated that enzyme 
replacement therapy with agalsidase alfa for 3 years might 
slow the decline in renal function in both male and females.43 
In women, the mean estimated glomerular filtration rate 
decline was 1.20 ± 3.28 mL/min/1.73 m2/year, with a mean 
reduction in estimated glomerular filtration rate over 3 years 
of 5.0 mL/min/1.73 m2 (P , 0.001).43
A single-center, open-label study of agalsidase alfa 
performed in 15 adult women with Fabry disease. In this 
clinical study by Baehner et al, female patients received 
enzyme replacement therapy for up to 55 weeks. Overall, 
agalsidase alfa in heterozygous females was demonstrated 
to regress left ventricular hypertrophy, improve quality of 
life, stabilize renal function, and reduce blood and urine 
glycolipid levels.84 Similarly, this study confirmed previous 
reports in male Fabry patients pertaining to the safety and 
pharmacokinetics of agalsidase alfa.84 A significant decrease 
in left ventricular mass index from baseline was observed at 
27 weeks (P = 0.003) and 41 weeks (P = 0.039), and a sig-
nificant reduction in QRS interval was observed at week 27 
(P = 0.007).84 Significant improvements in physical and 
general health subscales and the physical component score 
of the Short Form-36 questionnaire were also reported after 
6 months of agalsidase alfa treatment.84 Evaluation of these 15 
women continued in a 4-year, open-label extension study to 
evaluate the long-term response of females with Fabry disease 
to agalsidase alfa treatment.  A total of 40 female patients were 
evaluated. Overall, in this long-term evaluation of the effects 
of enzyme replacement therapy on kidney function in women 
with Fabry disease, agalsidase alfa appeared to stabilize or 
improve estimated glomerular   filtration rate in this cohort.6 
Patients with Stage I and III chronic kidney disease remained 
mostly stable during the treatment period, only one of nine 
Stage I chronic kidney disease patients progressed to Stage II 
chronic kidney disease, and none of the Stage III chronic 
kidney disease patients (n = 3) showed disease progression.6 
The subgroup of patients (n = 20) with moderately reduced 
kidney function at baseline (Stage II) showed a significant 
increase in estimated glomerular filtration rate after 1 year 
of treatment, which remained improved during 4 years of 
treatment.6 Six women who initiated angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers during 
the study demonstrated stable estimated glomerular filtration 
rate thereafter.6
Proteinuria has been reported in approximately 41% of 
women enrolled in the Fabry Outcome Survey, compared 
with 54% of men, although women with Fabry disease rarely 
develop end-stage renal failure.48 Following 4 years of treat-
ment with agalsidase alfa, proteinuria was significantly 
reduced to a mean of 339 ± 230 mg/24 hours in 11 patients 
(35%) with proteinuria $300 mg/24 hours at baseline (mean 
858 ± 751 mg/24 hours, P , 0.01).6 Brief Pain Inventory 
severity scores were reduced from 4.6 ± 2.9 at baseline to 
3.3 ± 2.9 after 12 months (P = 0.001) and remained signifi-
cantly reduced during the 4-year study.6 Left ventricular 
hypertrophy (defined as left ventricular mass $48 g/m2.7) 
was present in 69% of females (25 of 36 patients) at baseline.6 
LVM/h was significantly reduced after 12 months of 
agalsidase alfa treatment in these 25 females with baseline 
left ventricular hypertrophy. Of these 25 patients, 13 (52%) 
experienced decreases in LVM/h .20%, seven (28%) dem-
onstrated decreases in LVM/h of 10%–20%, and two (8%) Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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demonstrated decreases between 7.2 and 3.5%. After 4 years 
of treatment, seven of 25 patients with baseline left ven-
tricular hypertrophy were classified as having normal 
LVM/h.6 Only one of the subgroup of 11 females with normal 
baseline LVM/h (47.7 g/m2.7) was reclassified as having left 
ventricular hypertrophy at study completion (50.3 g/m2.7).6 
Based on the results from the Fabry Outcome Survey, 
  Whybra et al suggest that women with any signs or symp-
toms of Fabry disease should be considered for enzyme 
replacement therapy.6
Effects in children
Observations from pediatric studies are consistent with 
the safety and efficacy profiles reported for agalsidase 
alfa in adults.2,20,22,115 Efficacy and safety results of an 
initial 23-week, multicenter, open-label Fabry Outcome 
  Survey trial in nine boys and four girls have been reported.2 
The median age at treatment initiation was 11 years, and 
agalsidase alfa 0.2 mg/kg was administered as a 40-minute 
infusion every 2 weeks. Only one male patient developed 
IgG antibodies during treatment.2 In this study, agalsidase 
alfa was well tolerated, and infusion-associated reactions 
were mild and resolved without sequelae.2 At baseline, all 
boys had increased plasma Gb3 levels, whereas plasma 
Gb3 concentrations were all within the normal range 
for girls.2 After 12 and 23 weeks of treatment, plasma 
Gb3 levels decreased to near normal levels in boys and 
declined slightly in girls. For all boys, the mean urinary 
Gb3:sphingomyelin ratio decreased from 4.6 at baseline to 
2.5 after 23 weeks of   treatment.2 In girls, the mean urinary 
Gb3:sphingomyelin ratio decreased from 0.7 at baseline 
to 0.3 at week 23.2 The study also demonstrated reduced 
Brief Pain Inventory scores for “pain at its worst” from a 
mean baseline score of 2.8 to 1.5 at week 23, and “pain 
on average” from a mean baseline score of 2.2 to 0.9 at 
week 23.2 Pain-related quality of life scores, including 
interference of pain on general activity, mood, walking abil-
ity, normal work, relationships, and enjoyment of life also 
decreased, and eight patients reported no pain interference 
in any quality of life categories at study end.2 Increased 
sweat volumes were recorded after 23 weeks of treatment 
with agalsidase alfa.2 Six of 10 patients who experienced 
acroparesthesia at baseline reported an improvement after 
23 weeks of agalsidase alfa treatment.2
Similar clinical benefits have been documented in 
a second open-label study, which assessed the efficacy 
and safety of agalsidase alfa treatment for six months 
in 24 children with a mean age of 11.8 years.22 Overall, 
renal function remained normal following six months of 
enzyme replacement therapy (mean baseline estimated 
glomerular filtration rate = 121 ± 5.0 mL/min/1.73 m2 
and mean estimated glomerular filtration rate after 
26 weeks = 116 ± 3.9 mL/min/1.73 m2).22 Mean plasma Gb3 
was significantly reduced among the 19 boys with elevated 
baseline fasting plasma Gb3 (P , 0.001).22 In contrast, 
plasma Gb3 levels did not change among the five girls 
with normal baseline plasma Gb3 concentrations.22 Cardiac 
structure and function were normal and did not change during 
the study.22 In both boys and girls, mean LVM/h showed 
a nonsignificant decrease after 25 weeks of treatment.22 
Of note, three children with high-normal LVM/h at baseline 
(.40 g/m2.7, two girls and one boy) demonstrated a 15% 
mean decrease in LVM/h after 25 weeks of enzyme replace-
ment therapy.22 Heart rate variability, which was decreased in 
boys compared with girls at baseline, improved significantly 
in boys.22 In addition, 55% of patients who were receiving 
anticonvulsive medication for neuropathic pain were able to 
decrease or cease their consumption.22
Long-term extension data of the latter study have been 
recently published.20 Schiffmann et al demonstrated that 
agalsidase alfa treatment for 4 years was well tolerated in 
children.20 Twenty-four children (19 boys and five girls), 
10 of whom were treated for 4 years, showed significant 
reductions in pain scores, as well as sustained and improved 
heart rate variability in boys, estimated glomerular filtration 
rate, and LVM/h, which remained stable throughout the 
4-year study period.20 Overall, .93% of adverse events were 
reported as mild or moderate in severity for the 24 patients, 
and ,10% were deemed by the study investigators to be 
possibly related (6.5%) or probably related (3.4%) to study 
treatment.20 Only one male patient tested positive for IgG 
antibodies during this study.20
Ramaswami et al have recently evaluated the safety 
of enzyme replacement therapy with agalsidase alfa in 
young children enrolled in the Fabry Outcome Survey.85 
This retrospective chart review identified eight children 
(mean age 5.0 ± 1.6 years) in the Fabry Outcome Survey 
who began treatment with agalsidase alfa 0.2 mg/kg intra-
venously every other week when younger than 7 years. 
Vital signs and adverse events were monitored throughout 
the study period. Glomerular filtration rate was estimated, 
and LVM/h (2.7) was assessed using echocardiography. 
Patients received 1.2–6.7 years of treatment (mean 4.2 years). 
  Infusion reactions occurred in three patients and were of 
mild or moderate severity. IgG antibodies to agalsidase alfa 
were found in one patient who experienced two mild and Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
166
Ramaswami
one moderate infusion reactions. Mean glomerular filtration 
rate was within the normal range at baseline and remained 
normal. Left ventricular mass index was above the 75th 
percentile for age-matched children in five of six patients 
evaluated at baseline. Only two patients exceeded this thresh-
old at their last assessment. This study further emphasizes 
the importance of early diagnosis and follow-up of children 
with Fabry disease.85 The burden of Fabry disease in children 
is mostly due to neurological manifestations.34 Despite the 
small number of pediatric patient studies, Fabry Outcome 
Survey results to date reveal an overall improvement in pain, 
with either improvement or no change from baseline in most 
patients.34 Infusion-associated reactions in pediatric Fabry 
Outcome Survey patients were generally mild and similar 
to those reported in adults.34
Early diagnosis is paramount, because renal pathology has 
been described even in young children (age range 7–18 years) 
who may have not yet developed overt   proteinuria or decline 
in glomerular filtration rate; overt proteinuria has been 
reported in children as young as 10 years of age.86–88 Tøndel 
et al performed kidney biopsies in nine children, including 
two boys receiving enzyme replacement therapy.86 Notably, 
accumulation of Gb3 was found in nearly 7/9 (80%) of the 
young patients as well as glomerular, interstitial, or vascu-
lar lesions, even prior to the development of clinical renal 
functional impairment.86 However, 7/9 patients also had 
early onset microalbuminuria, thus emphasizing the impor-
tance of regular and early renal follow-up.86 Other pediatric 
studies have highlighted the importance of accurate diagnosis 
and careful monitoring for Fabry disease, because specific 
symptoms have been associated with greater disease severity 
and poorer prognosis.89,90 For example, retinal vascular 
tortuosity has been recognized as a predictive factor of a more 
severe illness in Fabry children.89,91 Allen et al investigated 
the correlation with Fabry genotype and systemic disease 
severity in children with ophthalmic manifestations.89 
Overall, ophthalmic manifestations were found in 76% of 
children predicted to have complete loss-of-function α-Gal A 
mutations (P = 0.003) and in only one patient with a genotype 
predicted to give some residual α-Gal A function.89 Thirteen 
(50%) of the 26 Fabry children were found to have corneal 
verticillata.89 Seven children (27%) had evidence of retinal 
vascular tortuosity.89 All seven children (four girls and 
three boys) had more severe systemic disease suggestive 
of autonomic neuropathy, such as diarrhea and syncope.89 
In another Fabry Outcome Survey study that investigated the 
epidemiology of hearing impairment and tinnitus in children 
with Fabry disease, Keilmann et al reported greater disease 
severity scores, measured by signs and symptoms question-
naires, in children with tinnitus.90
Comparator studies: agalsidase beta 
versus agalsidase alfa
The clinical outcomes of agalsidase beta or agalsidase alfa 
in Fabry disease have been measured in a number of inde-
pendent studies against a variety of endpoints. Most of these 
studies measured subclinical parameters rather than clinical 
outcomes per se.92 Both formulations are reported to provide 
several clinical benefits in the treatment of Fabry disease. 
However, comparison of therapeutic efficacy between the two 
distinct products is limited, probably due to the small number 
of randomized controlled trials, the small number of patients 
enrolled in these studies, different patient inclusion criteria, 
disease heterogeneity, short trial durations, as well as differ-
ences in outcome parameters and infused doses.28,35,93,94
To date, direct in vitro studies or studies in mice have 
shown no important differences between the two available 
enzyme preparations.24,25,28,35,95–98 A few recent head-to-head 
clinical studies of the relative efficacies of agalsidase beta 
compared with agalsidase alfa have been conducted.28,94,99,100 
These trials are summarized in Table 2.
Vedder et al conducted an open-label prospective study 
comparing agalsidase alfa at its registered dose of 0.2 mg/kg 
every other week with an equivalent dose of agalsidase beta 
at 0.2 mg/kg every other week.28 The primary endpoint 
for this study was reduction in left ventricular mass after 
1 and 2 years of enzyme replacement therapy. Twenty-six 
of the 29 patients enrolled had baseline left ventricular 
hypertrophy (13/14 subjects in the agalsidase alfa group 
and 13/15   subjects in the agalsidase beta group). There was 
no difference in median cardiac mass between groups at 
baseline (P = 0.48). Overall, changes in left ventricular mass 
(P = 0.3) and other disease parameters did not differ between 
the two groups following 1–2 years of enzyme replacement 
therapy. A slightly increased decline in left ventricular mass 
observed in the agalsidase beta group (15% versus 11% after 
12 months and 11% versus 5% at 24 months, for beta versus 
alfa, respectively) was not deemed statistically significant by 
the study authors.28 Vedder et al also reported that α-gal A 
antibodies in male adults occurred in approximately one-
third of treated patients, but twice as often (P = 0.005) with 
agalsidase beta when dosed at 1.0 mg/kg every other week 
(8/10 patients) compared with agalsidase alfa at 0.2 mg/kg 
every other week (4/10 patients). This difference was not 
observed with agalsidase beta at the lower dose of 0.2 mg/kg 
every other week (6/10 patients).99Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Consistent with other studies, none of the female 
patients developed antibodies.99 However, the impact of 
antibody formation on long-term clinical outcome remains 
unclear.99 A recent paper by Bénichou et al analyzed the 
potential impact of IgG antibodies to agalsidase beta on 
efficacy following 5 years of enzyme replacement therapy.101 
No correlation was found between anti-α-Gal A IgG titers and 
the onset of clinical events or the rate of change in estimated 
glomerular filtration rate.101 A statistically significant associa-
tion was observed between anti-α-Gal A IgG titers and Gb3   
deposition in skin fibroblasts during treatment, suggesting 
impairment of Gb3 clearance in some patients with high 
antibody titers.101 Determination of the long-term impact 
of circulating anti-α-Gal A antibodies on clinical outcomes 
requires continued monitoring during treatment.101
In a similar cohort of patients, Van Breeman et al recently 
described that agalsidase alfa 0.2 mg/kg every other week, 
agalsidase beta 0.2 mg/kg every other week, and agalsidase 
beta 1.0 mg/kg every other week resulted in marked decreases 
in elevated plasma Gb3 in Fabry males within three months 
(P = 0.0313), after which levels stabilized.100
The Canadian Fabry Disease Initiative is a large random-
ized controlled trial that has been initiated to provide robust 
multicenter national data on the natural history of the disease 
and on the comparative efficacy of agalsidase alfa and beta in 
enzyme replacement therapy-naïve Fabry patients.94 Multiple 
variables are to be studied during the 10-year treatment 
investigation. Several published abstracts have reported 
preliminary data for the 244 enrolled patients, and showed 
no significant differences in clinical outcomes at up to year 3 
between the two forms of agalsidase treatment.94,102,103 Future 
publication of this data will be particularly important to assess 
safety and clinical efficacy.
Safety and tolerability
The most common adverse events with agalsidase alfa are 
infusion-associated reactions, which occur in approximately 
13.7% of treated Fabry patients in clinical trials.16,29,48 These 
adverse events are typically mild to moderate in severity, 
and include rigors, fever, nausea and vomiting, headache, 
chest pain, flushing, pruritus, rhinitis, tremor, dyspnea, 
somnolence, and acroparesthesia.6,16,48 The Fabry Outcome 
Survey data, based on treatment of 314 patients, described 
serious adverse events in 27 male and 11 female subjects, 
which were deemed not related to agalsidase therapy by the 
treating physician.48 Most of these events were attributed to 
the natural progression of Fabry disease, and included strokes, 
transient ischemic attacks, arrhythmias, renal dysfunction, 
vertigo, and sudden deafness.48 Combined analysis of long-
term clinical trials shows that IgG antibodies have been 
observed in approximately 24% of the male patients after 
3–12 months of treatment with agalsidase alfa, but no IgE 
antibodies or anaphylactic reactions have been noted.29 Inter-
estingly, 7% of treated patients demonstrate immunological 
tolerance based on the disappearance of IgG   antibodies over 
time.34,104 Antibodies to agalsidase alfa have not been shown 
to be associated with any clinically significant effects on 
safety or efficacy.29 Consistent with other studies, a long-term 
study of the efficacy and tolerability of agalsidase alfa in 36 
female Fabry patients detected no antibodies during the treat-
ment period.6 In vitro studies demonstrate that IgG antibod-
ies cross-react similarly with both agalsidase alfa and beta, 
resulting in neutralization of α-Gal A activity.34,105 Safety 
and tolerability with long-term agalsidase alfa treatment 
has been demonstrated, and no additional safety concerns 
have been raised in children or females. No safety concerns 
have been described for   agalsidase alfa infusions used in the 
home setting.2,42,44
Outstanding management issues
The overall goal of enzyme replacement therapy is to prevent 
disease in younger patients, and to potentially halt disease 
progression and reverse underlying pathologic abnormalities 
in patients with more advanced disease.106–108 Results from 
clinical trials to date have highlighted that early initiation of 
enzyme replacement therapy may have the potential to delay 
and reverse the underlying clinical outcomes, such as renal 
failure, in patients with Fabry disease.18,42 Moreover, the use 
of enzyme replacement therapy in children is well tolerated, 
decreases pain, and improves pain-related quality of life.2,20,22 
However, long-term follow-up is necessary to ascertain 
whether starting treatment in childhood will prevent and/or 
stabilize end organ damage and increase life expectancy.35
The possibility to halt or even reverse the progress of 
Fabry disease before irreversible damage organ occurs 
necessitates accurate and rapid diagnosis, monitoring, and 
treatment of the disease.89 Difficulties in comparing clear-
ance of Gb3 and monitoring the clinical efficacy of enzyme 
replacement therapy in treated patients are highlighted by 
the wide variety of methodologies utilized in the studies 
to date. A reliable early biomarker or predictor of disease 
  progression for both genders would prove valuable in this 
regard.35 The novel plasma biomarker, globotriaosylsphin-
gosine (lyso-Gb3), is currently being studied as a poten-
tial biomarker for Fabry disease.109 Studies to date report 
increased plasma lyso-Gb3 in male patients, which was Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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higher in cases of the classic phenotype, whereas plasma 
lyso-Gb3 was moderately increased in females, and this 
correlated with a decrease in α-Gal A activity.109 Monitoring 
of microalbuminuria is currently recommended in Fabry 
patients, and could be readily used as a predictive indicator 
of early renal disease.88 Early changes in renal morphology 
can occur in adults and children with normal glomerular 
filtration rate.86,110 Precise assessment of glomerular filtration 
rate is therefore critical for early diagnosis, monitoring and 
treatment of nephropathy in these patients.88 Renal biopsy has 
been suggested as a potential tool to assess kidney disease 
severity accurately in pediatric Fabry patients, but further 
evaluation of this invasive procedure is warranted.86,88 Recent 
evaluation of different estimated glomerular filtration rate 
formulae, such as the Modification of Diet in Renal Disease 
method and the Schwartz formula commonly used in adult 
and pediatric Fabry patients, respectively, report overestima-
tion of glomerular filtration rate, especially in the early stages 
of chronic kidney disease; it has been suggested that all Fabry 
Outcome Survey estimated glomerular filtration rate data in 
children be recalculated using the new abbreviated Schwartz 
measured glomerular filtration rate formula.88,111 The widely 
acknowledged lack of precision of estimated glomerular fil-
tration rate measurements, particularly in pediatric patients, 
emphasizes the need for consensus guidelines and more 
accurate diagnostic tools.88,111
Consensus guidelines and recommendations for enzyme 
replacement therapy in Fabry patients have been published 
but, based on more recent data including Fabry Outcome 
Survey analyses, require updating.112–114 The European 
Medicines Agency have also issued treatment guidelines for 
patients with Fabry disease following continued shortages 
of agalsidase beta, which include adjusted dose regimens 
for adult male and female patients to 0.3 mg/kg every other 
week, switching to and starting treatment-naïve patients on 
alternative treatments, such as agalsidase alfa.115 A similar 
approach had been adopted for a shortage of Cerezyme® 
(imiglucerase for injection; Genzyme Corporation) for 
the treatment of Gaucher’s disease.115 These extraordi-
nary shortage circumstances have required a rapid global 
adaptation to current management strategies from industry, 
funding bodies, clinicians, patient organizations, and patients 
themselves.115 Due to the rarity of Fabry disease and the small 
numbers of patients available to be enrolled in large-scale, 
placebo-controlled clinical trials, data from registries, such as 
the Fabry Outcome Survey, are extremely valuable to further 
our understanding about the effect of enzyme replacement 
therapy in Fabry patients. Analysis of all randomized trials, 
open-label studies, and Fabry Outcome Survey data to date 
demonstrate clinical benefits of agalsidase alfa compared 
with placebo and provide further understanding of the 
natural history of Fabry disease, as well as the long-term 
safety of enzyme replacement therapy. Overall, agalsidase 
alfa treatment appears to be positively related to patients’ 
health-related quality of life, ameliorating the natural course 
of the disease.35 However, the value of enzyme replacement 
therapy for event-free survival, incidence and severity of 
comorbidities, as well as sustained improvement of patient 
health-related quality of life is not yet realized.35
Enzyme replacement therapy is a lifelong treatment for 
patients with Fabry disease, and home therapy has been 
proven to be beneficial for patients’ quality of life whilst 
optimizing health care resources. The benefit of a 40-minute 
infusion and good safety profile of agalsidase alfa in adults 
and children has been regarded as more convenient in a home 
setting.42 Most patients in the UK have enzyme replacement 
therapy at home, and home care providers have experienced 
specialist nurses who provide this service, liaising closely with 
hospital clinicians and nurses.116 Recent studies have shown 
home infusion with agalsidase alfa to be   convenient, and 
less   stressful, as well as having a positive impact on patient 
satisfaction and possible cost reduction.42,116 The quality of 
evidence differs vastly between the   studies mentioned in this 
review, from randomized controlled trials that are relatively 
short in duration, to open-label follow-up, and to registry 
data, which rely on good quality   retrospective data, which 
has its own limitations. As a result, further randomized 
controlled studies may be required to define the appropriate 
time to initiate enzyme replacement therapy, as well as the 
optimal treatment dose for the individual patient.35 Careful 
and individualized treatment planning should be guided 
by accurate and earlier diagnosis of patients and timely 
assessment of organ damage. A study of two agalsidase beta 
dosing regimens in treatment-naïve male pediatric patients 
without severe symptoms will examine the efficacy and 
safety of two lower-dose regimens of Fabrazyme in male 
patients aged 5–18 years over the course of 5 years. Data 
from this study, described as Fabrazyme: Intervening Early 
at a Lower Dose (FIELD), may provide further supporting 
evidence for early and more flexible treatment, especially 
in pediatric patients and/or those with milder symptoms for 
Fabry disease.117
Preliminary data from the Canadian Fabry Disease Initia-
tive suggest no significant differences in efficacy or safety 
between the two enzyme replacement therapy preparations. 
Owing to the recent production difficulties with agalsidase Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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beta, further evaluation of a balanced and factual com-
parison of these two drugs may be hindered.115 In addition, 
there is a lack of in vitro studies available to allow relevant 
comparisons.
The systemic nature of Fabry disease necessitates a mul-
tidisciplinary management approach involving, for example, 
cardiologists, nephrologists, pediatricians, neurologists, ear, 
nose and throat specialists, psychologists, and specialist 
nurses. Other needs of Fabry patients and their families, 
such as genetic counseling and family screening, and treat-
ment options such as home-based therapy should also be 
made available, because these are likely to have a positive 
impact on quality of life.34 In addition to enzyme replacement 
therapy, adjunctive therapies should be integrated, such as 
the use of appropriate analgesia for neuropathic pain, anti-
hypertensives and the use of angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers for proteinuria, 
because these currently play an essential part in the optimal 
management of Fabry disease.16
Conclusion
Fabry disease is a slowly progressive disease with clinical 
manifestations often occurring in early childhood. Currently, 
in the absence of a suitable biomarker to establish the rate 
and severity of disease progression, monitoring patients 
regularly, both adults and children, for the onset of renal, 
cardiac, and central nervous system manifestations is essen-
tial to determine the timing of enzyme replacement therapy 
and adjunctive therapy. Over the past decade, the use of 
enzyme replacement therapy in patients with Fabry disease 
has significantly improved their quality of life and delays/
stabilizes disease progression.
Given the cost of enzyme replacement therapy and the 
burden of treatment over a prolonged period of time, it is 
vitally important to analyze long-term follow-up data to 
determine the point of no return with respect to disease pro-
gression, and thus optimizing the timing for   commencing 
enzyme replacement therapy. Consensus guidelines of when 
to initiate enzyme replacement therapy are limited because 
of the rarity of the disease and a lack of reliable controlled 
studies designed to confirm the appropriate timing of ini-
tiation of enzyme replacement therapy. However, based on 
personal clinical experience, as well as recently published 
literature, the author’s view is that initiation of enzyme 
replacement therapy must be considered carefully in a 
selected group of children with Fabry disease who have no 
residual enzyme activity and/or manifest early disease-related 
symptoms which significantly affect their quality of life. 
These patient have a very high likelihood of developing 
significant complications related to Fabry disease.
Allen et al also correlated early ocular manifestations 
with genotype and overall disease severity in children with 
Fabry disease.89 Absent alfa-galactosidase A activity and 
genotype with loss of function mutations seem to be the best 
predictors of disease progression that we have in children 
currently, together with family history of a tendency to 
develop early strokes, and renal and cardiac complications. 
Once signs and symptoms develop, irreversible damage has 
probably already occurred. Regular follow-up will also enable 
clinicians to detect early evidence of cardiac, renal, or central 
nervous system disease in children, such as increase in left 
  ventricular mass index above age-appropriate centiles, early 
onset of microalbuminuria, retinal vessel tortuosity, uncon-
trolled neuropathic pain, and recurrent fever pain   crises. It is 
recommended that both male and female pediatric patients 
who remain asymptomatic in early childhood must have 
regular follow-up assessments at least once a year.
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